Northway Biotech
VILNIUS, LITHUANIA / ACCESSWIRE / November 16, 2023 / Northway Group is embarking on a project to establish Europe's largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes - 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres - that will be built in an area equivalent to 10 football fields. The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.
Northway Group is in the process of constructing Europe's largest biotechnology hub, with the inaugural Gene Therapy Center set to be operational in 2024.
"A science-based economy, supported by bright minds and intelligent entrepreneurs, is the foundation for Lithuania's long-term economic prosperity. In the past, our growth was constrained by a lack of fossil resources, but today, we are boldly moving forward, relying on modern technologies. The new biotechnology hub embodies the direction of Lithuania's innovative economy. It also promises new inventions that will enable people with serious illnesses to become full members of society, thereby reducing exclusion," says the President of the Republic of Lithuania, Gitanas Nausėda.
Prof. Vladas Algirdas Bumelis, founder and CEO of Northway Biotech and Celltechna, key components of the Northway Group, highlighted Lithuania's strong global standing in biotechnology. The aim of the BIO CITY project is to further solidify this position with four advanced biomanufacturing facilities and two innovative research centres, significantly boosting Lithuania's prominence in the international biotech sphere.
The Speaker of the Seimas, parliament of Lithuania, states that the new biotech city being developed in Vilnius will strengthen the competitiveness of our country. "Lithuanian life sciences industry has ambitions and potential to become a global leader in this field: a leader who will significantly contribute to the development of scientific research for the well-being of man, nature and planet, and will facilitate new opportunities to deal with global health, sustainable development and other challenges," says Viktorija Čmilytė-Nielsen.
Vision of BIO CITY: A European Biotechnology Leader
"We envision BIO CITY as a frontrunner in the European biotechnology, by uniquely integrating various biotech segments into a single, synergistic ecosystem. This multifunctional complex will catalyse interdisciplinary collaborations, the quick realisation of ideas and technological advancements. Our unique model, which brings together diverse biotechnology fields in one location, is set to revolutionise the European biotech landscape," said Prof. V. A. Bumelis.
Gene Therapy Centre will Open in 2024
The first facility to open its doors in the biotech hub BIO CITY will be the Gene Therapy Centre, which is currently under construction and is being built by Northway Group's subsidiary, Celltechna. This centre, the first and so far the only one of its kind in the Baltic States, will bolster Lithuania's role in gene therapy, addressing the needs of the 280 million individuals worldwide who are affected by genetic diseases.
"Our state-of-the-art facility will be instrumental in both research and production, offering new treatments for previously incurable diseases. This will not only augment our CDMO (Contract Development and Manufacturing Organisation) capabilities, but also position us for global competition and collaborations," added Prof. V. A. Bumelis.
The Gene Therapy Centre, which is expected to become operational in the second quarter of 2024, will specialise in gene therapy research and GMP manufacturing. Representing an investment of 50 million euros, the facility will span 8,000 square metres and is anticipated to create over 100 high-value jobs. The centre will work in synergy with Northway Biotech. Established in 2004, Northway Biotech is a leading provider of CDMO services in the field of biologics, with a focus on the development and manufacturing of recombinant proteins and antibodies.
A Comprehensive Lithuanian Biotech Hub
By 2030, BIO CITY will see the inauguration of five additional complexes, including centres for R&D and Virology, Life Sciences Industry Smart Services, Stem Cell Research and 3D Bioprinting, as well as two large-scale production centres for mammalian and microbial products. The entire BIO CITY complex will span an area equivalent to 10 football fields, with the total investment expected to reach around 7 billion euros over the next decade.
"We will not only focus on contract development and manufacturing services, but will also invest significantly in the operation of scientific research centres. Scientific activity enhances a country's competitiveness and generates value in various forms, beyond just the economic aspect. Modern biotechnologies, such as gene editing and cell therapies, are advancing rapidly. Lithuania can pride itself on having some of the most talented scientists and robust expertise in these areas. The development of the biotech campus in Vilnius means we are poised to foster new partnerships with innovative startups, research institutions and pharmaceutical companies on a global scale. We are actively seeking partnerships and offer a warm invitation to investors who are enthusiastic about joining this exciting venture," said Prof. V. A. Bumelis.
Upon its completion, BIO CITY is expected to offer employment to approximately 2,100 highly skilled professionals, including scientists, biotechnologists, and medical engineers.
Lithuania is Among the Leaders in the Global Biotechnology Market
The global biotechnology market, currently valued at over 1,130 billion euros, is anticipated to grow to be worth more than 2,775 billion euros by 2030. Lithuania holds a strong position in this market, ranking among the Top 35 innovative countries in the biotechnology field, according to Scientific American Worldview.
"Every year, Lithuania is mentioned in the field of Life Sciences more often, and the ambitious BIO CITY project will contribute to our leadership. Our vision is coming to life - we are talking about world-class Life Sciences infrastructure and a competitive sector capable of building innovative products. In 2022, companies in the sector posted combined revenues of 1.5 billion euros, while exporting their goods to more than 100 countries. Overall, Life Sciences is a leading sector in Lithuania, when it comes to creating and implementing innovative solutions," states Aušrinė Armonaitė, the Minister of the Economy and Innovation.
Over 80 life science companies operate in Lithuania, contributing about 2.5% to the country's GDP. The Northway group, a key player in Lithuania's biotech sector, manages seven companies: five in Lithuania and one each in the UK and the US, with the US entity being recognised as the largest biotech investor from the Baltic region in recent years. Employing more than 200 specialists, these companies provide services to a diverse array of international biopharmaceutical firms, ranging from small to large enterprises, predominantly operating in both Europe and the US.
BIO CITY Contacts:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Contact Information:
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Related Files
BIO CITY LOGO_ORANGE.png
BIO CITY LOGO_BLACK.png
Related Images
SOURCE: Northway Healthcare Group
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/804258/the-largest-biotech-city-in-europe-will-soon-be-built-with-an-investment-amounting-to-7-billion-euros
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Gun, Cocaine, and a High-Speed Chase: Luton Crime Haul Sparks Fresh Questions and Public Appeal11.7.2025 13:45:00 CEST | Press release
Officers discovered an estimated 25 kilograms of suspected Class A drugs, tightly packed and hidden in secret compartments. Alongside the drugs, they recovered a Beretta 92FS 9mm semi-automatic handgun, loaded with 38 rounds of ammunition. LUTON, GB / ACCESS Newswire / July 11, 2025 / A dramatic police pursuit through Luton on the night of June 29 resulted in the seizure of a loaded firearm and an estimated £600,000 worth of suspected cocaine. Nearly a week later, crucial questions remain unanswered, and police are still searching for individuals who fled the scene. The incident, which unfolded between 11:30 PM and 1:00 AM, began in Marsh Farm when Bedfordshire Police officers attempted to stop a vehicle as part of a proactive investigation into organised criminal activity. The driver failed to stop, sparking a high-speed chase that stretched through Dallow, Farley Hill, and eventually ended on Beechwood Road, where the vehicle was forcibly brought to a halt. Inside, officers discovere
The Battery Show Europe Showcases Global Acceleration10.7.2025 10:00:00 CEST | Press release
Europe's flagship event advancing the battery and EV industry from cell design to policy frameworks STUTTGART, GERMANY / ACCESS Newswire / July 10, 2025 / The Battery Show Europe and Electric & Hybrid Vehicle Technology Expo Europe, co-located with Energy Storage Summit Germany (ESG), welcomed over 17,000 industry professionals and more than 1,100 exhibitors to Messe Stuttgart. This combined event represents the only place where the entire advanced battery, electric & hybrid vehicle technology and energy storage supply chain can be accessed under one roof. From breakthrough technologies and policy insights to hands-on demos and global partnerships, the 2025 edition captured the rapid pace of industry evolution and the growing international significance. Keynote sessions across the three-day event featured high-profile speakers from across the battery, automotive and energy sectors, including BMW Group, Verkor, Mercedes-Benz, CATL and Shanghai Putailai New Energy Technology Co., Ltd. Th
Eagle Football Chairman John Textor Congratulates Olympique Lyonnais on Qualification for Ligue 1 and UEFA Europa League9.7.2025 18:55:00 CEST | Press release
PALM BEACH GARDENS, FL / ACCESS Newswire / July 9, 2025 / John Textor, Chairman and CEO of Eagle Football Holdings, today issued the following statement in response to the decision by the French Football Federation (FFF) to uphold Olympique Lyonnais's (OL) appeal, reversing the earlier decision of the DNCG, and confirming OL's participation in Ligue 1 and UEFA Europa League: John Textor, Chairman and majority owner of Eagle Football Holdings, stated: "I would like to congratulate our whole team at Olympique Lyonnais for demonstrating clearly what we have long known, that our great club in Lyon is financially strong and ready to continue its climb up the tables in France and in Europe. We previously cleared through a rigorous sustainability review by UEFA, and now, under the remarkable leadership of our Chair Michele Kang, OL has succeeded on appeal, in cooperation with the DNCG, to confirm our place in Ligue 1 and in Europa League." He continued, "Today's decision is a vital recognitio
Sandline Global Expands International Presence with New London Office9.7.2025 15:15:00 CEST | Press release
LONDON, GB / ACCESS Newswire / July 9, 2025 / Sandline Global, a leading provider of legal technology, eDiscovery, and litigation support services, is proud to announce the opening of its new office in London. This milestone marks a strategic expansion of Sandline's international footprint and reinforces the company's commitment to serving clients across the UK and broader EMEA region.Sandline Global Logo Sandline Global Logo The decision to establish a permanent presence in London was driven by significant and sustained demand for Sandline's services in the region. With a growing number of cross-border matters and increasing interest in Sandline's capabilities-including digital forensics, eDiscovery services, and managed review-the new location will enable the company to deliver tailored, more localized support to clients with complex legal and regulatory needs. "Our expansion into London reflects both the strength of our partnerships in the UK and our long-term vision for internation
Agassi Sports Entertainment Engages IBM to Help Elevate Racquet Sports Experience9.7.2025 14:30:00 CEST | Press release
LAS VEGAS, NV / ACCESS Newswire / July 9, 2025 / Agassi Sports Entertainment Corp. (OTC PINK:AASP), an emerging leader in sports entertainment and innovation, is pleased to announce an exciting collaboration with IBM (NYSE:IBM) which includes the planned use of AI aimed at transforming the digital landscape for various racquet sports worldwide. As two iconic brands with strong connections to racquet sports, and a shared commitment to excellence, Agassi Sports Entertainment has engaged IBM to help create what Agassi Sports Entertainment believes will be an unrivaled digital experience that caters to players and fans alike. This relationship represents a unique fusion of passion, technology, and innovation that Agassi Sports Entertainment expects will not only enhance the way people engage with racquet sports but will also elevate the sport's overall accessibility and enjoyment. Our joint efforts are planned to focus on harnessing cutting-edge technology to deliver personalized experienc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom